Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Connective Tissue and its Growth Factor, CTGF, Distinguish the Morphometric and Molecular Remodeling of the Bladder in a Model of Neurogenic Bladder.
Studies of EN-1639A (naltrexone): a new narcotic antagonist.
Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress.
[Posture disorders in patients with multiple sclerosis.]
[Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal.]
Impact of intermittent catheterization on the quality of life of multiple sclerosis patients.
DMDs Are an Essential Issue But Are They the Only Issue in MS Treatment?
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Influence of cigarette smoking on white matter in patients with clinically isolated syndrome as detected by diffusion tensor imaging.
1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization.
Can smoking aggravate my multiple sclerosis symptoms?
Is multiple sclerosis a proresolution deficiency disorder?
[Cannabinoid drugs for neurological diseases: what is behind?].
[Gluten-related disorders and demyelinating diseases.]
Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
Human Endogenous Retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods.
High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
IgM antibody identifies good candidates for natalizumab
[Sexuality of men with neurologic disorders].
Optical coherence tomography in multiple sclerosis.
Intraventricularly injected Olig2-NSCs attenuate established relapsing-remitting EAE in mice.
Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis.
Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination.
In Active Relapsing-Remitting Multiple Sclerosis, Effector T Cell Resistance to Adaptive Tregs Involves IL-6-Mediated Signaling.

Pages